Systemic sclerosis is a chronic autoimmune disease in which the body’s immune system triggers widespread thickening and scarring of the skin and internal organs. It affects women roughly three to four times more often than men, with symptoms typically appearing in the mid-40s. Though relatively rare, it can involve the lungs, digestive tract, kidneys, and heart, making it one of the more serious autoimmune conditions.
What Happens in the Body
Systemic sclerosis unfolds through three interconnected processes: damage to small blood vessels, immune system activation, and excessive production of collagen (the protein that gives skin and tissues their structure). These three events feed off one another, creating a cycle that progressively stiffens tissues throughout the body.
The process starts with swelling and injury to the cells lining small blood vessels. This attracts immune cells, which cluster around the damaged vessels and release inflammatory signals. Over time, specialized cells called myofibroblasts become overactive and lay down dense bundles of collagen where it doesn’t belong. The result is fibrosis: tissue that becomes thick, hard, and less able to function normally. This fibrosis is what makes the skin feel tight and what gradually impairs organ function when it occurs internally.
Limited vs. Diffuse Subtypes
Doctors classify systemic sclerosis into two main forms based on how much skin is affected. This distinction matters because the two subtypes carry different risks, progress at different speeds, and tend to involve different organs.
Limited cutaneous systemic sclerosis involves skin thickening that stays below the elbows and knees, and may affect the face and neck. It often progresses slowly over years. The biggest long-term risk with the limited form is pulmonary arterial hypertension (high blood pressure in the lung arteries), which can develop 5 to 10 or more years after diagnosis. Kidney crisis is uncommon in this subtype.
Diffuse cutaneous systemic sclerosis involves widespread skin thickening that extends above the elbows and knees and can cover the trunk. This form tends to progress faster, with more rapid internal organ involvement. It carries a higher risk of lung scarring and kidney crisis, and historically has lower survival rates. Five-year survival is about 85.5% for diffuse disease compared with 86.6% for the limited form. At 10 years, the gap widens: roughly 70% for diffuse versus 79% for limited.
What Antibodies Reveal About Risk
Blood tests for specific antibodies do more than confirm a diagnosis. They help predict which organs are most likely to be affected, giving doctors a head start on monitoring.
- Anticentromere antibodies are most common in the limited subtype. They signal a lower risk of lung scarring but a clearly increased risk of pulmonary arterial hypertension, particularly after 5 to 10 years of disease.
- Anti-topoisomerase I (Scl-70) antibodies are strongly linked to interstitial lung disease, the type of lung scarring that can reduce breathing capacity. People with this antibody tend to develop lung involvement earlier and with faster decline in lung function during the initial years.
- Anti-RNA polymerase III antibodies carry a markedly elevated risk of scleroderma renal crisis, a sudden and dangerous spike in blood pressure that can damage the kidneys. This antibody is also associated with cancer clustering around the time of diagnosis, particularly breast cancer and blood cancers.
Raynaud’s Phenomenon: Often the First Sign
For many people, the earliest clue is Raynaud’s phenomenon, in which fingers (and sometimes toes) turn white or blue in response to cold or stress, then flush red as blood flow returns. This happens because the small blood vessels overreact and spasm shut. In systemic sclerosis, Raynaud’s can appear years before any skin changes or other symptoms develop.
Calcium channel blockers, particularly nifedipine, are the standard first-line treatment. A large analysis of 38 clinical trials confirmed they significantly reduce the frequency and severity of attacks. A second class of medications, PDE5 inhibitors, has also shown meaningful improvements in attack frequency and duration for people who don’t respond well to calcium channel blockers alone.
Lung Involvement
The lungs are one of the most commonly and seriously affected organs. Interstitial lung disease, in which scar tissue builds up in the lung walls and makes it harder to exchange oxygen, occurs in an estimated 26% to 88% of patients depending on the population studied and how it’s detected. This wide range partly reflects that early lung scarring can show up on imaging before a person notices any breathing difficulty.
Treatment options have expanded considerably. Mycophenolate is now recommended as the first-line therapy for long-term stabilization of lung function. An immune-targeting drug, tocilizumab, showed a meaningful 4.2% preservation of lung capacity in clinical trials, earning FDA approval specifically for systemic sclerosis-related lung disease. Nintedanib, an antifibrotic medication, reduced the annual rate of lung function decline by 41 milliliters per year compared to placebo in a major trial, making it an important option for slowing progression. Rituximab, which depletes certain immune cells, has shown consistent benefits in multiple trials while causing fewer side effects than older alternatives.
Digestive Problems
Gastrointestinal symptoms are extremely common, affecting the esophagus, stomach, and intestines. The digestive tract is lined with smooth muscle, and when fibrosis stiffens that muscle, food doesn’t move through the way it should.
The most frequently reported symptom is bloating, affecting nearly 88% of patients in one study. Acid reflux and difficulty swallowing are common because the esophagus loses its ability to push food downward effectively. Between 20% and 50% of patients experience intestinal symptoms like diarrhea and constipation, and 20% to 40% develop fecal incontinence, a symptom that significantly affects quality of life but is often underreported. Gastroparesis, where the stomach empties too slowly, causes early fullness, nausea, vomiting, and abdominal pain. In advanced disease, these digestive problems can contribute to weight loss and malnutrition.
Kidney Crisis
Scleroderma renal crisis is one of the most dangerous complications, though it occurs in a minority of patients. It involves a sudden spike in blood pressure along with rapidly declining kidney function. Microangiopathic hemolytic anemia, a condition where red blood cells are destroyed as they pass through damaged small vessels, can develop swiftly alongside rising creatinine levels. Counterintuitively, blood pressure may be normal initially before escalating quickly.
This complication is most closely associated with the diffuse subtype and with anti-RNA polymerase III antibodies. People with these risk factors are typically monitored with regular blood pressure checks and kidney function tests so that any crisis can be caught and treated early.
Skin and Overall Disease Management
Skin thickening is the hallmark feature, and its severity is used to track disease activity over time. Several treatments can help. Rituximab showed striking results in the DESIRES trial, reducing skin thickness scores by 6.3 points compared to a worsening of 2.1 points with placebo. Mycophenolate, initially studied for lung disease, also improves skin fibrosis comparably to older, harsher immune-suppressing drugs.
For severe, rapidly progressive disease, autologous stem cell transplant represents the most effective option currently available. Multiple randomized trials have consistently demonstrated its superiority over conventional immune suppression in improving long-term skin outcomes and survival. It’s a high-intensity treatment with real risks, but for carefully selected patients with aggressive disease, the long-term benefits have been significant.
Living With Systemic Sclerosis
This is a disease measured in years and decades, not weeks. The 10-year survival rate across subtypes ranges from roughly 70% to 82%, and outcomes have been improving as treatments advance. The leading causes of death are lung involvement (both scarring and pulmonary hypertension) and heart complications, which underscores why regular screening of these organs is a core part of ongoing care.
Because systemic sclerosis can affect so many organ systems simultaneously, most people end up working with a team that includes a rheumatologist, pulmonologist, and gastroenterologist at minimum. The specific antibody profile, subtype, and pattern of organ involvement all shape which monitoring and treatments make the most sense for a given individual. Early detection of internal organ changes, before symptoms become obvious, is what allows treatment to do the most good.